HOME >> BIOLOGY >> NEWS
Other highlights from the April 18 Journal of the National Cancer Institute

New Culture Technique Could Lead to Drug Discoveries

A novel cell culture technique for a noninvasive breast malignancy known as ductal carcinoma in situ (DCIS) could facilitate the discovery of new drugs to prevent DCIS recurrence or progression.

Gillian Farnie, Ph.D, of the University of Manchester in England, and colleagues developed a novel method to culture DCIS cells, and using this method, they examined the role of the epidermal growth factor receptor and Notch signaling pathways in the growth of DCIS. They found that both pathways were involved in self-renewal of DCIS cells; the former was necessary for DCIS growth, and the latter was important for cell survival.

"To our knowledge, no culture technique for DCIS exists; thus, the nonadherent culture technique that we describe should be useful for isolating tumor-forming epithelial cells from their primary DCIS lesions to allow a better understanding of their growth," the authors write.

Contact: Gillian Farnie, Ph.D, of the University of Manchester, 0161 446 3212, Gillian.Farnie@manchester.ac.uk


Shortened HER2 Gene Responds to Lapatinib, Not Trastuzumab

Breast cancer cells expressing a shortened form of the HER2 gene can be treated with lapatinib, but they are resistant to another drug known as trastuzumab.

HER2 is a gene in the epidermal growth factor receptor family that plays a role in regulating cell growth. In about 15 to 20 percent of breast cancers, HER2 is overexpressed, and women with these kinds of tumors have a worse than average prognosis. Many breast cancers that express HER2 are resistant to the HER2 antibody trastuzumab, a drug often used to treat HER2-positive breast cancer. Some are resistant because they express p95HER2, a shortened form of the receptor that cannot bind to trastuzumab.

Maurizio Scaltriti, of the Vall d'He
'"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
17-Apr-2007


Page: 1 2

Related biology news :

1. Other highlights in the Aug. 7 JNCI
2. Other highlights in the July 24 JNCI
3. Other highlights from the July 10 JNCI
4. Other highlights in JNCI, June 26
5. Other highlights in JNCI, June 12
6. Other highlights from the June 6 JNCI
7. Other highlights in the May 16 JNCI
8. Other highlights from the March 21 JNCI
9. Other highlights in the March 7 JNCI
10. Other highlights in the Feb. 21 JNCI
11. Other highlights in the Jan. 17 JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... July 08, 2020 , ... ... and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 ... study, but what is the most effective way to complete one? Will the ...
(Date:7/2/2020)... (PRWEB) , ... July 01, 2020 , ... ... presented its phase 1a findings of Neihulizumab, a biologic for the treatment of ... June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, ... glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments of its ... are charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... WILMINGTON, Del. (PRWEB) , ... August 29, 2020 ... ... of a new Animal Nutrition manufacturing capability in Wuxi, China. The new plant ... DuPont’s global quality standards and advanced technology. , “This facility will improve ...
(Date:8/15/2020)... ... August 13, 2020 , ... ... 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. The ... economy’s most dynamic segment—its independent small businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... engineering firm, is making available for free its new white paper – ... transport simulation testing into today’s biologics licensing application (BLA). In response, Modality ...
(Date:8/7/2020)... WOODLANDS, Texas (PRWEB) , ... August 06, 2020 ... ... therapy and DNA vaccine industries, announces it has closed on the purchase of ... Technology Park in Conroe, TX and includes over 21 acres in the initial ...
Breaking Biology Technology:
Cached News: